Summers Laboratories, Inc. v. Shionogi Inc.

CourtDistrict Court, S.D. New York
DecidedJanuary 27, 2020
Docket1:19-cv-02754
StatusUnknown

This text of Summers Laboratories, Inc. v. Shionogi Inc. (Summers Laboratories, Inc. v. Shionogi Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Summers Laboratories, Inc. v. Shionogi Inc., (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT USDC SDNY SOUTHERN DISTRICT OF NEW YORK DOCUMENT SUMMERS LABORATORIES, INC., ELECTRONICALLY FILED Pentionss -against- 19 Civ. 2754 (AT) SHIONOGI INC., ORDER Respondent. ANALISA TORRES, District Judge: Petitioner, Summers Laboratories, Inc. (“Summers”), brings this petition under the Federal Arbitration Act (the “FAA”), 9 U.S.C. § 9, to confirm a unanimous arbitration award (the “Award”) issued on March 1, 2019, in an arbitration between Summers and Respondent, Shionogi Inc. (“Shionogi”). Petition § 1, ECF No. 6. Respondent has not paid Petitioner amounts due under the Award relating to attorney’s fees, costs, and interest. Jd. 921. Accordingly, Petitioner seeks this Court’s confirmation of the Award, and the entry of judgment in favor of Petitioner and against Respondent. Jd. { 27. Respondent moves to vacate the Award to the extent it awarded attorney’s fees. Resp. Opp. at 1, ECF No. 25. For the reasons stated below, the petition to confirm the Award is GRANTED and the motion to partially vacate the Award is DENIED. BACKGROUND! Petitioner is a pharmaceutical product company located in Collegeville, Pennsylvania. 56.1 § 2, ECF No. 25-1. Respondent is the successor in interest to Sciele Pharma Cayman Ltd. (“Sciele Cayman”) and Sciele Pharma, Inc. (“Sciele Pharma”). Jd. § 4. On July 16, 2007, Petitioner, Sciele Cayman, and Sciele Pharma entered into a set of “[t]ransaction [d]ocuments” to effectuate the Asset Purchase Agreement (the “APA”) between the parties. /d. 7. As part of the transaction, the

! The following facts are drawn from the parties’ pleadings and submissions, including the Petition, Petitioner’s Rule 56.1 statement of undisputed fact and Respondent’s response, Respondent’s counter-statement of facts and Petitioner’s response, and the parties’ declarations. Facts in dispute are so noted. Citations to a paragraph in Petitioner’s Rule 56.1 statement also include Respondent's response.

parties executed: (1) the APA; (2) the bill of sale; (3) the patent and trademark assignment; and (4) the guaranty and surety agreement (the “Guaranty”); the latter three are exhibits to the APA. Id. ¶¶ 8–9. The APA was executed by Sciele Cayman and the Guaranty was executed by Sciele Pharma, the parent company of Sciele Cayman; both of which were later acquired by Respondent. Id. ¶¶ 12–13, 20–21. Through this acquisition, Respondent became the successor of Sciele Cayman, the principal of the APA, and Sciele Pharma, the guarantor under the Guaranty. Counter-Statement of Facts ¶ 65, ECF No. 27. The APA provided for the sale of certain intellectual property and related rights by Petitioner to Sciele Cayman that would become Ulesfia, a product for the treatment of head lice. 56.1 ¶ 14. Under

the APA, Sciele Cayman, and later Respondent, as successor in interest, was required to make certain payments to Petitioner upon satisfaction of specific conditions. Id. ¶ 15. Under the APA, Respondent is not required to make minimum payments to Petitioner under two circumstances, as defined in the APA: (1) if net sales reach or exceed certain levels or (2) if the failure to reach or exceed certain net sales levels is the result of a “market change.” Id. ¶ 17. At issue in the arbitration were certain yearly minimum payments that were not made by Respondents. Id. ¶ 16. In 2017, Respondent concluded that a market change had occurred, and therefore, that no minimum payment had been due in January 2017 for the calendar year 2016. Id. ¶ 24. On July 28, 2017, Petitioner submitted its demand for arbitration (the “Demand”) to the American Arbitration

Association (the “AAA”). Id. ¶ 26. Petitioner’s submission included the AAA “Commercial Arbitration Rules Demand for Arbitration” form with checked boxes requesting attorney’s fees, interest, and arbitration costs. Id. ¶ 27. Along with the Demand, Petitioner submitted a complaint requesting attorney’s fees and costs, attaching a complete set of transaction documents, which included the APA and the Guaranty. Id. ¶ 28. Respondent filed its answer and counterclaims on August 30, 2017. Id. ¶ 29. Petitioner claims that in its answer, Respondent did not object to Petitioner’s request for attorney’s fees; Respondent disputes this, noting that Respondent stated a general denial to all of Petitioner’s claims for relief. Id. ¶ 31. The APA provides that the arbitration panel will be made up of three arbitrators, one selected by Petitioner, one selected by Respondent, and one selected by mutual agreement of the arbitrators who were selected by the Petitioner and Respondent. APA § 8.5(b), ECF No. 20-6. The arbitration panel (the “Panel”) included the Honorable Shira Scheindlin (Petitioner’s selection), Harrie Samaras (Respondent’s selection), and Edna Sussman (mutually selected).2 See 56.1 ¶¶ 34–42. The arbitration hearing was conducted in New York City from July 23 to July 27. Id. ¶ 66. On October 22, 2018, the Panel issued its unanimous 40-page interim award (the “First Interim Award”).

Id. ¶ 75. The Panel concluded that no market change had occurred and, therefore, Respondent owed Petitioner the minimum payments required under the APA. Id. ¶ 78. The Panel elected to address certain issues, such as attorney’s fees, separately. Id. ¶ 79. On October 22, 2018, the Panel directed the Parties to submit additional briefing relating to an award of attorney’s fees and costs raised by the Guaranty. ECF No. 20-44, at 3. Petitioner states that both the APA and the Guaranty were at issue in the Arbitration; Respondent disputes this fact and contends that only the APA was at issue. Id. ¶ 11. The APA provision relevant to the parties’ current dispute, Section 8.5(e), provides: The expenses of the arbitration shall be borne by the Parties in proportion as to which each Party prevails or is defeated in arbitration. Each Party shall bear the expenses of its counsel and other experts.

APA § 8.5(e). The relevant provisions of the Guaranty, paragraphs 1 and 2, provide that Sciele Pharma (and later Shionogi), the guarantor, shall: irrevocably and unconditionally guarantee[] the prompt payment and performance of all debts, liabilities, obligations . . . arising under the [p]urchase [a]greement” and “shall pay or reimburse . . . all reasonable costs and expenses, including, without limitation reasonable

2 Judge Scheindlin was selected after Petitioner’s first selection, the Honorable James T. Giles, recused himself from the case. 56.1 ¶ 41–42. a[ptt]oarrntye’ys[ ’rsig] hfetse sh,e irnecuunrdreedr. at any time to enforce, protect, preserve, or defend [g]uaranteed

Guaranty at 40, ECF No. 20-6; see also 56.1 ¶ 23.3 On December 26, 2018, the Panel issued its 17-page Second Interim Award, deciding to award Petitioner attorney’s fees under the Guaranty. 56.1 ¶ 87. With respect to Respondent’s argument that it was not on notice of Petitioner’s request for attorney’s fees, the Panel concluded that “[Respondent] had adequate notice of [Petitioner’s] claim for attorney[’s] fees and that such a claim was asserted pursuant to the Guaranty.” Second Interim Award at 52, ECF No. 20-3.4 The Panel also considered Respondent’s claim that the award of attorney’s fees is precluded by the APA. Id. at 53. The Panel determined that Respondent’s “reliance on [the] language [of § 8.5(e)] is misplaced.” Id. at 53. The Panel reasoned that: “Party” and “Parties,” to which [§] 8.5(e) applies, are expressly defined in the APA as including only Summers, the Seller and Sciele Pharma Cayman Ltd., the Buyer and principal obligor. The obligation undertaken by the guarantor, Sciele Pharma, Inc., was a separate contractual obligation under the Guaranty. Thus [§] 8.5(e) of the APA, by its terms, does not apply to the [g]uarantor.

Id.; see also 56.1 ¶ 94.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Summers Laboratories, Inc. v. Shionogi Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/summers-laboratories-inc-v-shionogi-inc-nysd-2020.